메뉴 건너뛰기




Volumn 172, Issue 1, 2016, Pages 23-31

New products for the treatment of haemophilia

Author keywords

Bleeding disorders; Coagulation; Coagulation factors; Haemophilia

Indexed keywords

ALBUMIN; ANTIBODY; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A I16L; BLOOD CLOTTING FACTOR 10A V17A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G4 ANTIBODY; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN;

EID: 84955478863     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13797     Document Type: Review
Times cited : (15)

References (63)
  • 1
    • 0034651022 scopus 로고    scopus 로고
    • Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
    • Barrow, R.T., Healey, J.F., Gailani, D., Scandella, D. & Lollar, P. (2000) Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood, 95, 564-568.
    • (2000) Blood , vol.95 , pp. 564-568
    • Barrow, R.T.1    Healey, J.F.2    Gailani, D.3    Scandella, D.4    Lollar, P.5
  • 2
    • 77953158260 scopus 로고    scopus 로고
    • Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice
    • Bolliger, D., Szlam, F., Suzuki, N., Matsushita, T. & Tanaka, K.A. (2010) Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thrombosis & Haemostasis, 103, 1233-1238.
    • (2010) Thrombosis & Haemostasis , vol.103 , pp. 1233-1238
    • Bolliger, D.1    Szlam, F.2    Suzuki, N.3    Matsushita, T.4    Tanaka, K.A.5
  • 5
    • 78650988916 scopus 로고    scopus 로고
    • Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
    • Bunce, M.W., Toso, R. & Camire, R.M. (2011) Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood, 117, 290-298.
    • (2011) Blood , vol.117 , pp. 290-298
    • Bunce, M.W.1    Toso, R.2    Camire, R.M.3
  • 6
    • 0033214353 scopus 로고    scopus 로고
    • "Normal" thrombin generation
    • Butenas, S., van't Veer, C. & Mann, K.G. (1999) "Normal" thrombin generation. Blood, 94, 2169-2178.
    • (1999) Blood , vol.94 , pp. 2169-2178
    • Butenas, S.1    van't Veer, C.2    Mann, K.G.3
  • 7
    • 0344420226 scopus 로고    scopus 로고
    • Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
    • Caliceti, P. & Veronese, F.M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews, 55, 1261-1277.
    • (2003) Advanced Drug Delivery Reviews , vol.55 , pp. 1261-1277
    • Caliceti, P.1    Veronese, F.M.2
  • 11
    • 84898028710 scopus 로고    scopus 로고
    • Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
    • Coyle, T.E., Reding, M.T., Lin, J.C., Michaels, L.A., Shah, A. & Powell, J. (2014) Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. Journal of Thrombosis and Haemostasis, 12, 488-496.
    • (2014) Journal of Thrombosis and Haemostasis , vol.12 , pp. 488-496
    • Coyle, T.E.1    Reding, M.T.2    Lin, J.C.3    Michaels, L.A.4    Shah, A.5    Powell, J.6
  • 13
    • 84931956043 scopus 로고    scopus 로고
    • Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
    • Dodt, J., Hubbard, A.R., Wicks, S.J., Gray, E., Neugebauer, B., Charton, E. & Silvester, G. (2015) Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia, 21, 543-549.
    • (2015) Haemophilia , vol.21 , pp. 543-549
    • Dodt, J.1    Hubbard, A.R.2    Wicks, S.J.3    Gray, E.4    Neugebauer, B.5    Charton, E.6    Silvester, G.7
  • 15
    • 84870496347 scopus 로고    scopus 로고
    • The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
    • Finn, J.D., Nichols, T.C., Svoronos, N., Merricks, E.P., Bellenger, D.A., Zhou, S., Simioni, P., High, K.A. & Arruda, V.R. (2012) The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 120, 4521-4523.
    • (2012) Blood , vol.120 , pp. 4521-4523
    • Finn, J.D.1    Nichols, T.C.2    Svoronos, N.3    Merricks, E.P.4    Bellenger, D.A.5    Zhou, S.6    Simioni, P.7    High, K.A.8    Arruda, V.R.9
  • 17
    • 84860317799 scopus 로고    scopus 로고
    • Porcine factor VIII
    • Giangrande, P.L. (2012) Porcine factor VIII. Haemophilia, 18, 305-309.
    • (2012) Haemophilia , vol.18 , pp. 305-309
    • Giangrande, P.L.1
  • 18
    • 0036845615 scopus 로고    scopus 로고
    • Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy
    • Hakeos, W.H., Miao, H., Sirachainan, N., Kemball-Cook, G., Saenko, E.L., Kaufman, R.J. & Pipe, S.W. (2002) Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thrombosis & Haemostasis, 88, 781-787.
    • (2002) Thrombosis & Haemostasis , vol.88 , pp. 781-787
    • Hakeos, W.H.1    Miao, H.2    Sirachainan, N.3    Kemball-Cook, G.4    Saenko, E.L.5    Kaufman, R.J.6    Pipe, S.W.7
  • 19
    • 84922385618 scopus 로고    scopus 로고
    • FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in haemophilic animal models
    • PO-TU-025
    • Hart, G., Monahan, P., Seligsohn, U., Zakar, M., Hershkovitz, O., Bar-Ilan, A. & Fima, E. (2012) FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in haemophilic animal models. Haemophilia, 18(S3), 32. PO-TU-025.
    • (2012) Haemophilia , vol.18 , pp. 32
    • Hart, G.1    Monahan, P.2    Seligsohn, U.3    Zakar, M.4    Hershkovitz, O.5    Bar-Ilan, A.6    Fima, E.7
  • 20
    • 0029909770 scopus 로고    scopus 로고
    • The cDNA and derived amino acid sequence of porcine factor VIII
    • Healey, J.F., Lubin, I.M. & Lollar, P. (1996) The cDNA and derived amino acid sequence of porcine factor VIII. Blood, 88, 4209-4214.
    • (1996) Blood , vol.88 , pp. 4209-4214
    • Healey, J.F.1    Lubin, I.M.2    Lollar, P.3
  • 24
    • 84871015919 scopus 로고    scopus 로고
    • PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
    • Ivens, I.A., Baumann, A., McDonald, T.A., Humphries, T.J., Michaels, L.A. & Mathew, P. (2013) PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia, 19, 11-20.
    • (2013) Haemophilia , vol.19 , pp. 11-20
    • Ivens, I.A.1    Baumann, A.2    McDonald, T.A.3    Humphries, T.J.4    Michaels, L.A.5    Mathew, P.6
  • 25
    • 84871660904 scopus 로고    scopus 로고
    • Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
    • Kannicht, C., Ramstrom, M., Kohla, G., Tiemeyer, M., Casademunt, E., Walter, O. & Sandberg, H. (2013) Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thrombosis Research, 131, 78-88.
    • (2013) Thrombosis Research , vol.131 , pp. 78-88
    • Kannicht, C.1    Ramstrom, M.2    Kohla, G.3    Tiemeyer, M.4    Casademunt, E.5    Walter, O.6    Sandberg, H.7
  • 31
    • 84930274386 scopus 로고    scopus 로고
    • Role of enhanced half-life factor VIII and IX in the treatment of haemophilia
    • Mahdi, A.J., Obaji, S.G. & Collins, P.W. (2015) Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. British Journal of Haematology, 169, 768-776.
    • (2015) British Journal of Haematology , vol.169 , pp. 768-776
    • Mahdi, A.J.1    Obaji, S.G.2    Collins, P.W.3
  • 33
    • 84899557335 scopus 로고    scopus 로고
    • Anti-drug antibody formation in haemophilia patients with inhibitors afterreceiving recombinant activated FVII analogue (vatreptacog alfa)
    • on behalf of the Adept Investigators. PO029.
    • Mahlangu, J., Karim, F.A., Gorska-Kosicka, M., Kaicker, S., Matsushita, T., Recht, M., Serban, M., Kentz, S., Weldingh, K.N. & Ehrenforth, S.; on behalf of the Adept Investigators. (2013) Anti-drug antibody formation in haemophilia patients with inhibitors afterreceiving recombinant activated FVII analogue (vatreptacog alfa). Haemophilia, 19, 10-82 PO029.
    • (2013) Haemophilia , vol.19 , pp. 10-82
    • Mahlangu, J.1    Karim, F.A.2    Gorska-Kosicka, M.3    Kaicker, S.4    Matsushita, T.5    Recht, M.6    Serban, M.7    Kentz, S.8    Weldingh, K.N.9    Ehrenforth, S.10
  • 36
  • 37
    • 84887009302 scopus 로고    scopus 로고
    • Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
    • Metzner, H.J., Pipe, S.W., Weimer, T. & Schulte, S. (2013) Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thrombosis & Haemostasis, 110, 931-939.
    • (2013) Thrombosis & Haemostasis , vol.110 , pp. 931-939
    • Metzner, H.J.1    Pipe, S.W.2    Weimer, T.3    Schulte, S.4
  • 40
    • 80052669248 scopus 로고    scopus 로고
    • Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
    • Negrier, C., Knobe, K., Tiede, A., Giangrande, P. & Møss, J. (2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood, 118, 2695-2701.
    • (2011) Blood , vol.118 , pp. 2695-2701
    • Negrier, C.1    Knobe, K.2    Tiede, A.3    Giangrande, P.4    Møss, J.5
  • 42
    • 84870336472 scopus 로고    scopus 로고
    • Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study
    • Powell, J., Martinowitz, U., Windyga, J., Di Minno, G., Hellmann, A., Pabinger, I., Maas Enriquez, M., Schwartz, L. & Ingerslev, J. (2012a) Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thrombosis and Haemostasis, 108, 913-922.
    • (2012) Thrombosis and Haemostasis , vol.108 , pp. 913-922
    • Powell, J.1    Martinowitz, U.2    Windyga, J.3    Di Minno, G.4    Hellmann, A.5    Pabinger, I.6    Maas Enriquez, M.7    Schwartz, L.8    Ingerslev, J.9
  • 45
    • 33845549376 scopus 로고    scopus 로고
    • Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays
    • Radtke, K.P., Griffin, J.H., Riceberg, J. & Gale, A.J. (2007) Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. Journal of Thrombosis & Haemostasis, 5, 102-108.
    • (2007) Journal of Thrombosis & Haemostasis , vol.5 , pp. 102-108
    • Radtke, K.P.1    Griffin, J.H.2    Riceberg, J.3    Gale, A.J.4
  • 48
  • 49
    • 84866594053 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
    • Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I. & Morfini, M. (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 120, 2405-2411.
    • (2012) Blood , vol.120 , pp. 2405-2411
    • Santagostino, E.1    Negrier, C.2    Klamroth, R.3    Tiede, A.4    Pabinger-Fasching, I.5    Voigt, C.6    Jacobs, I.7    Morfini, M.8
  • 50
    • 84878831095 scopus 로고    scopus 로고
    • The immunogenicity of polyethylene glycol: facts and fiction
    • Schellekens, H., Hennink, W.E. & Brinks, V. (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharmaceutical Research, 30, 1729-1734.
    • (2013) Pharmaceutical Research , vol.30 , pp. 1729-1734
    • Schellekens, H.1    Hennink, W.E.2    Brinks, V.3
  • 51
    • 84875518350 scopus 로고    scopus 로고
    • Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII
    • Schulte, S. (2013) Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thrombosis Research, 131, S2-S6.
    • (2013) Thrombosis Research , vol.131 , pp. S2-S6
    • Schulte, S.1
  • 54
    • 34447314172 scopus 로고    scopus 로고
    • Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
    • Shetty, S., Vora, S., Kulkarni, B., Mota, L., Vijapurkar, M., Quadros, L. & Ghosh, K. (2007) Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. British Journal of Haematology, 138, 541-544.
    • (2007) British Journal of Haematology , vol.138 , pp. 541-544
    • Shetty, S.1    Vora, S.2    Kulkarni, B.3    Mota, L.4    Vijapurkar, M.5    Quadros, L.6    Ghosh, K.7
  • 58
    • 84876182114 scopus 로고    scopus 로고
    • Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA
    • Tiede, A., Brand, B., Fischer, R., Kavakli, K., Lentz, S.R., Matsushita, T., Rea, C., Knobe, K. & Viuff, D. (2013) Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA. Journal of Thrombosis & Haemostasis, 11, 670-678.
    • (2013) Journal of Thrombosis & Haemostasis , vol.11 , pp. 670-678
    • Tiede, A.1    Brand, B.2    Fischer, R.3    Kavakli, K.4    Lentz, S.R.5    Matsushita, T.6    Rea, C.7    Knobe, K.8    Viuff, D.9
  • 60
    • 53449102315 scopus 로고    scopus 로고
    • Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface
    • Wakabayashi, H., Varfaj, F., Deangelis, J. & Fay, P.J. (2008) Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood, 112, 2761-2769.
    • (2008) Blood , vol.112 , pp. 2761-2769
    • Wakabayashi, H.1    Varfaj, F.2    Deangelis, J.3    Fay, P.J.4
  • 62
    • 84896919120 scopus 로고    scopus 로고
    • Discussion about several potential drawbacks of PEGylated therapeutic proteins
    • Zhang, F., Liu, M.R. & Wan, H.T. (2014) Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biological and Pharmaceutical Bulletin, 37, 335-339.
    • (2014) Biological and Pharmaceutical Bulletin , vol.37 , pp. 335-339
    • Zhang, F.1    Liu, M.R.2    Wan, H.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.